


Lithium Binaphtholate-Catalyzed Asymmetric Addition of Lithium Acetylides to Carbonyl Compounds

Shunsuke Kotani,[†] Kenji Kukita,[‡] Kana Tanaka,[‡] Tomonori Ichibakase,[‡] and Makoto Nakajima^{*,†,‡,§}

[†]Priority Organization for Innovation and Excellence and [‡]Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan

Supporting Information




ABSTRACT: The asymmetric addition of lithium acetylides to carbonyl compounds in the presence of a chiral lithium binaphtholate catalyst was developed. A procedure involving the slow addition of carbonyl compounds to lithium acetylides improved the enantioselectivity. This reaction afforded diverse chiral secondary and tertiary propargylic alcohols in high yields and with good to high enantioselectivities.

INTRODUCTION

Organolithiums are versatile reagents and commonly used as nucleophiles or bases in organic synthesis.¹ The cationic property of lithium leads to higher reactivity than Grignard or organozinc reagents; however, this property is simultaneously disadvantageous for achieving high stereoselectivity. Lithium acetylide, an organolithium reagent, is used in alkynylations of carbonyl compounds to afford the corresponding propargylic alcohols that are useful building blocks in the synthesis of pharmaceuticals, agrochemicals, and natural products.¹ Therefore, asymmetric alkynylations have been developed.^{2,3} Because of recent significant progress in asymmetric catalysis, highly stereoselective alkynylations of terminal alkynes have been achieved using other metal cocatalysts such as Zn,^{4,5} Ti,⁶ Cu,⁷ and several other metals.⁸ However, the asymmetric alkynylation using lithium acetylides without other metals has been rarely examined despite the high reactivity of alkynyllithiums (Scheme 1). In 1979, Mukaiyama and co-workers developed the first enantioselective alkynylation with lithium acetylide in the absence of other metals.⁹ They used lithium acetylides and chiral ligands, affording propargylic alcohols with high enantioselectivity. In 1995, the enantio-

Scheme 1. Methods for Asymmetric Alkynylation of Carbonyl Compounds




selective alkynylation of ketones was applied to synthesize efavirenz, an HIV-1 reverse transcriptase inhibitor.^{10,11} In both cases, more than stoichiometric amounts of acetylide and ligand were required to achieve high enantioselectivity. Recently, we reported that a catalytic amount of chiral lithium binaphtholate complex efficiently catalyzed the asymmetric alkynylation of ketones with lithium acetylides, affording the corresponding tertiary propargylic alcohols with high enantioselectivity.¹² In this paper, we report the details of lithium binaphtholate-catalyzed enantioselective alkynylation of carbonyl compounds using a slow addition procedure, thus dramatically increasing the enantioselectivity.

RESULTS AND DISCUSSION

Survey of Substrates and Catalysts for Enantioselective Alkynylations. First, we investigated the addition of lithium phenylacetylide (**4u**) to benzaldehyde (**2a**) or acetophenone (**3a**) in the presence of 10 mol % of lithium binaphtholate (**1b**) (Table 1). Both the lithium reagents **1b** and **4u** were prepared in situ by adding *n*-butyllithium to a solution of (*R*)-3,3'-diphenyl-2,2'-binaphthol (**1b'**) and phenylacetylene (**4u'**) (Scheme 2). To the resulting solution was added a solution of carbonyl compound **2a** or **3a**, affording the corresponding propargylic alcohols **5au** or **6au**, respectively. In the toluene solution, no selectivity was observed in the alkynylation of **2a** and **3a** (Table 1, entries 1 and 3). In contrast, the reaction in THF afforded **5au** with moderate enantioselectivity (32% ee, Table 1, entry 2). Furthermore, the alkynylation of ketone **3a** afforded the corresponding tertiary


Received: March 6, 2014

Published: April 21, 2014

Table 1. Asymmetric Alkynylation of Carbonyl Compounds with Lithium Binaphtholate 1b^a

entry	carbonyl compd	solvent	yield (%)	ee ^b (%)
1	PhCHO (2a)	toluene	89	1
2		THF	95	32
3	PhCOCH ₃ (3a)	toluene	72	3
4		THF	87	67

^aThe reaction was conducted by adding a solution of carbonyl compound **2a** or **3a** over 1 min to a solution of acetylene **4u** (2.0 equiv), (*R*)-Ph₂-BINOL **1b** (10 mol%), and *n*-BuLi (2.0 equiv) in the above-mentioned solvent at 0 °C (entries 1 and 2) or at 23 °C (entries 3 and 4). ^bDetermined by chiral HPLC.


Scheme 2. In Situ Generation of Lithium Binaphtholate and Lithium Acetylide

alcohol **6au** with good enantioselectivity (67% ee, Table 1, entry 4).

Screening of BINOLs for the Asymmetric Alkynylation of Ketones. We investigated the alkynylation of ketone **3a** with lithium acetylide **4u** using diverse BINOLs **1** because the alkynylations of ketones have not been well established compared to those of aldehydes (Table 2). The parent BINOL (R = H, **1a**) was ineffective (Table 2, entry 1). Introduction of bromo, methyl, or different substituents on the phenyl group did not improve the enantioselectivity. The best result was obtained with **1b** (R = Ph). Since no enantioselectivity was achieved by using O-methylated BINOL derivatives **7** and **8** (structures shown below Table 2), a bisphenol motif is absolutely essential for the asymmetric alkynylation (Table 2, entries 9 and 10). When the reaction was performed at -78 °C, both the product yield and enantioselectivity dramatically increased (Table 2, entry 11). We reported these reaction conditions (standard conditions: catalyst, **1b**; solvent, THF; reaction temperature, -78 °C) in our previous communication.¹² After further detailed investigation, we discovered that a slow addition of a solution of ketone **3a** over 1 h (slow addition procedure) improved the enantioselectivity to 96% ee (Table 2, entry 12). A further increase in the addition time did not improve the enantioselectivity (Table 2, entry 13). Even when the catalyst loading was reduced to 2 mol %, the product was obtained without loss of both yield and enantioselectivity (Table 2, entry 14).


Asymmetric Alkynylation of Ketones with Alkynes.

With the optimized reaction conditions and catalyst **1b**, we performed the asymmetric alkynylation of various ketones **3** (Table 3). The results obtained by using standard conditions¹²


Table 2. Screening of Catalysts^a

entry	(R)-Li ₂ -BINOLs		yield (%)	ee ^b (%)
	1	R		
1	1a	H	90	2
2	1b	Ph	87	67
3	1c	Br	78	17
4	1d	Me	94	15
5	1e	4-tolyl	90	60
6	1f	3,5-xylyl	77	28
7	1g	4-FC ₆ H ₄	81	63
8	1h	4-MeOC ₆ H ₄	80	57
9	7	Ph	95	0
10	8	Ph	96	0
11 ^c	1b	Ph	96	92
12 ^{c,d}	1b	Ph	95	96
13 ^{c,e}	1b	Ph	91	96
14 ^{c,d,f}	1b	Ph	96	96

^aThe reaction was conducted by adding a THF solution of ketone **3a** over 1 min to a THF solution of **4u** (2.0 equiv), (*R*)-BINOL **1** (10 mol%), and *n*-BuLi (2.0 equiv) at rt. ^bDetermined by chiral HPLC. ^cAt -78 °C for 2 h. ^dA THF solution of ketone **3a** was added over 1 h. ^eA THF solution of ketone **3a** was added over 3 h. ^f2 mol % of **1b** was used.



(addition over 1 min) are also listed in Table 3 for comparison with those of the slow addition procedure (addition over 1 h). Ethyl ketone **3b** still afforded good enantioselectivity (Table 3, entry 2), whereas isopropyl ketone **3c** decreased the selectivity because of less enantiodifferentiation by ketone **3c** (Table 3, entry 3). Although *ortho*-substituted ketone **3d** slightly decreased the yield, high enantioselectivity was achieved in the reaction of tolylaldehydes **3d–f** irrespective of the substituent position (Table 3, entries 4–6). Aryl methyl ketones **3g–m** also afforded the corresponding tertiary propargylic alcohols in both high chemical and optical yields (Table 3, entries 7–13). In the reactions of ketones **3l** and **3m**, the slow addition procedure decreased the product yields (Table 3, entries 12 and 13). When the reactions were quenched with deuterium oxide, deuterated ketones **3l-d₂** and **3m-d₂** could be obtained. The observation indicated that the enolization of ketones was preferred over alkynylation because of low electrophilicity of the carbonyl groups (Figure 1).¹³ Even the alkynylation of ketone **3n**, with a small steric difference between the carbonyl substituents, afforded good enantioselectivity (Table 3, entry 14). The alkynylation of aliphatic ketone **3o** was successful, affording good enantioselectivity (Table 3, entry 15). Notably, ketones bearing heteroaromatic rings afforded high yields and enantioselectivity because other metal catalysts were less selective (Table 3, entries 16–18). Propargylic alcohol **6qu**, which exhibits antifungal activity,

Table 3. Asymmetric Alkynylation of Ketones^a

entry	ketone			standard conditions			slow addition procedure ^b	
	3	R ¹	R ²	6	yield (%)	ee ^c (%)	yield (%)	ee ^c (%)
1	3a	Ph	Me	6au	96	93	95	96
2	3b	Ph	Et	6bu	93	73	95	89
3 ^d	3c	Ph	ⁱ Pr	6cu	99	7	95	8
4	3d	2-MeC ₆ H ₄	Me	6du	53	87	66	91
5	3e	3-MeC ₆ H ₄	Me	6eu	97	94	90	96
6	3f	4-MeC ₆ H ₄	Me	6fu	93	88	94	96
7	3g	4-MeOC ₆ H ₄	Me	6gu	95	92	92	95
8	3h	4-CF ₃ C ₆ H ₄	Me	6hu	95	76	92	95
9	3i	4-FC ₆ H ₄	Me	6iu	89	91	93	95
10	3j	4-BrC ₆ H ₄	Me	6ju			94	94
11	3k	2-naphthyl	Me	6ku	94	85	93	93
12 ^d	3l	1-naphthyl	Me	6lu	76	70	21	78
13 ^d	3m	3,4,5-(MeO) ₃ C ₆ H ₂	Me	6mu	90	97	21	98
14	3n	PhCH ₂ CH ₂	Me	6nu	99	39	96	55
15	3o	ⁱ Pr	Me	6ou	95	33	89	81
16	3p	2-thienyl	Me	6pu			92	95
17	3q	3-pyridyl	Me	6qu	96	87	96	94
18	3r	4-pyridyl	Me	6ru	90	71	90	92

^aThe reaction was conducted by adding a THF solution of ketone 3 to a THF solution of alkyne 4u' (2.0 equiv), (R)-1b' (10 mol%), and *n*-BuLi (2.0 equiv) at -78 °C. ^bA THF solution of ketone 3 was added over 1 h. ^cDetermined by chiral HPLC. ^dFor 6 h.





Figure 1. Enolization of 3m with lithium acetylide.

could be readily synthesized.¹⁴ The slow addition procedure was quite efficient for diverse substrates, affording the corresponding products with improved enantioselectivity.

The alkynylations of diverse alkynes with acetophenone (3a) are summarized in Table 4. *n*-Alkynes such as 1-hexyne (4v) and 1-decyne (4w) afforded the corresponding tertiary propargylic alcohols in high yields and with good enantioselectivities (Table 4, entries 2 and 3). In the reaction of cyclohexenylacetylene (4x), excellent selectivity was obtained (Table 4, entry 4). Alkynes containing an oxygen or a silicon atom also afforded the corresponding products with high enantioselectivity (Table 4, entries 5 and 6). In the reaction with alkyne 4z, the slow addition procedure dramatically improved the enantioselectivity from 44% to 91% ee. This alkynylation method of ketones has a broad substrate scope in terms of both ketones and alkynes.

Determination of the Absolute Configuration of Chiral Tertiary Propargylic Alcohols. Several asymmetric alkynylations of ketones have been reported; however, the determination of the absolute configurations of tertiary propargylic alcohols has not been well established. This is because the volume of the optical rotation data of this series of compounds is small. To determine the absolute configurations, the derivatives of product 6 were prepared by following the procedure as shown in Scheme 3.¹⁵ Propargylic alcohol 6bu

Table 4. Asymmetric Alkynylation of Acetophenone with Alkynes^a


entry	lithium acetylide		standard conditions		slow addition procedure ^b		
	4	R ³	6	yield (%)	ee ^c (%)	yield (%)	ee ^c (%)
1	4u	Ph	6au	96	93	95	96
2	4v	ⁿ Bu	6av	89	87	95	90
3	4w	ⁿ octyl	6aw	92	86	99	92
4	4x	cyclohexenyl	6ax	80	84	99	95
5	4y	BnOCH ₂	6ay	97	86	99	87
6	4z	TMS	6az	88	44	93	91

^aThe reaction was conducted by adding a THF solution of ketone 3a to a THF solution of alkyne 4' (2.0 equiv), (R)-1b' (10 mol%), and *n*-BuLi (2.0 equiv) at -78 °C. ^bA THF solution of ketone 3 was added over 1 h. ^cDetermined by chiral HPLC.

was reduced with Red-Al to afford the corresponding allylic alcohol, followed by the ozonolysis and oxidation to afford the corresponding ester 7b. The optical rotation of 7b was compared with the reported value in the literature,¹⁶ and the absolute configuration of 4bu was determined to be *S*. Following the same procedure, the absolute configurations of several products were determined, resulting in the *S* configuration in all the cases.¹⁷


Asymmetric Alkynylation of Aldehydes with Alkynes. Because the slow addition procedure was quite efficient for the

Scheme 3. Derivatization of 6



alkynylation of ketones, we applied this procedure to the asymmetric alkynylation of aldehydes (Table 5). When the

Table 5. Effect of Slow Addition Procedure for the Alkynylation of Benzaldehyde 2a^a



entry	addition time	yield (%)	ee ^b (%)
1	1 min	96	49
2	10 min	97	75
3	1 h	91	74

^aThe reaction was conducted by adding a THF solution of aldehyde 2a over the above-mentioned addition time to a THF solution of alkyne 4u' (2.0 equiv), (R)- 1b' (10 mol%), and *n*-BuLi (2.0 equiv) at -78 °C. ^bDetermined by chiral HPLC.


asymmetric alkynylation of aldehyde 2a was performed with lithium acetylide 4u at -78 °C, the standard conditions afforded the corresponding product with only 49% ee (Table 5, entry 1). The slow addition procedure dramatically improved the enantioselectivity (Table 5, entries 2 and 3), and the best result was obtained by the addition over 10 min (Table 5, entry 2).

The reactions of diverse alkynes 4 with benzaldehyde (2a) were conducted (Table 6). The reactions of 1-hexyne (4v) and 1-decyne (4w) afforded almost racemic products (Table 6, entries 2 and 3). Moderate enantioselectivity was observed in the reaction with 1-cyclohexenylacetylene (4x) (Table 6, entry 4). The enantioselectivities of 3-(benzyloxy)prop-1-yne (4y) and (trimethylsilyl)acetylene (4z) were moderate (Table 6, entries 5 and 6).

Next, we investigated the alkynylation of diverse aldehydes 2 (Table 7). The nucleophilicity of lithium acetylide severely affected the product selectivity. The enantioselectivity of aromatic aldehydes depends on the steric and electronic effects of the substituents on the phenyl groups (Table 7, entries 2–5). Although the aldehydes with electron-withdrawing groups decreased the enantioselectivity, the aldehydes with electron-donating groups afforded good to high enantioselectivity. The best enantioselectivity was achieved in the reaction with 3,4,5-trimethoxybenzaldehyde (Table 7, entry 5). Aliphatic aldehyde 2f was less selective, affording moderate enantioselectivity (Table 7, entry 6).

Conclusion. The chiral lithium binaphtholate-catalyzed enantioselective alkynylation of ketones and aldehydes with lithium acetylides afforded the corresponding optically active tertiary propargylic alcohols with high enantioselectivity. In


Table 6. Asymmetric Alkynylation of Aldehydes with Alkynes^a



entry	lithium acetylide		secondary propargylic alcohol		
	4	R ²	5	yield (%)	ee ^b (%)
1	4u	Ph	5au	97	75
2	4v	"Bu	5av	99	15
3	4w	"octyl	5aw	94	21
4	4x	1-cyclohexenyl	5ax	92	61
5	4y	BnOCH ₂	5ay	98	42
6	4z	TMS	5az	91	44

^aThe reaction was conducted by adding a THF solution of aldehyde 2a over 10 min to a THF solution of an acetylene 4' (2.0 equiv), (R)- 1b' (10 mol%), and *n*-BuLi (2.0 equiv) at -78 °C. ^bDetermined by chiral HPLC.

Table 7. Asymmetric Alkynylation of Aldehydes with Alkynes^a



entry	aldehyde		secondary propargylic alcohol		
	2	R ¹	5	yield (%)	ee ^b (%)
1	2a	Ph	5au	97	75
2	2b	4-MeOC ₆ H ₄	5bu	99	75
3	2c	4-ClC ₆ H ₄	5cu	98	71
4	2d	2-naphthyl	5du	96	65
5	2e	3,4,5-(MeO) ₃ C ₆ H ₂	5eu	95	82
6	2f	"hex	5fu	90	58

^aThe reaction was conducted by adding a THF solution of aldehyde 2a over 10 min to a THF solution of an acetylene 4u' (2.0 equiv), (R)- 1b' (10 mol%), and *n*-BuLi (2.0 equiv) at -78 °C. ^bDetermined by chiral HPLC.

addition, we showed that the slow addition procedure efficiently improved the enantioselectivity. This procedure was useful for the alkynylation of carbonyl compounds with lithium acetylide without using other metals. The study paved the path to develop enantioselective reactions of organolithium reagents.

EXPERIMENTAL SECTION

Representative Procedure for Asymmetric Alkynylations of Ketones. Lithium acetylide **4u** and lithium binaphtholate **1b** were prepared by the addition of *n*-BuLi (1.65 M in hexane, 0.52 mL, 0.86 mmol) to the solution of (*R*)-3,3'-diphenyl-1,1'-binaphthalene-2,2'-diol (19 mg, 0.043 mmol) and phenylacetylene (0.10 mL, 0.86 mmol) in THF (1.0 mL) at -78°C . To the resulting solution was added acetophenone (**3a**) (0.05 mL, 0.43 mmol) in THF (1.0 mL) over 1 h at the same temperature, and the resulting solution was stirred for an additional 3 h. After being quenched with saturated aq NH_4Cl , the reaction mixture was extracted with EtOAc. The organic layer was washed with saturated aq NaHCO_3 and saturated aq NaCl. After drying over Na_2SO_4 , the solvent was removed under vacuum, and the residue was purified by silica gel column chromatography (hexane/ $\text{CH}_2\text{Cl}_2 = 1/1$) to afford **6au** (90.2 mg, 95% yield) as an oil. The enantiomeric excess (ee) was determined to be 96% by chiral HPLC with Daicel Chiralcel OD-H column.

(*S*)-(-)-2,4-Diphenylbut-3-yn-2-ol (**6au**). The experimental data are in accordance with those reported in the previous literature.¹⁵ 90.2 mg (95% yield). $[\alpha]_{\text{D}}^{30} -7.4$ (c 1.3, CHCl_3) for 96% ee [lit. $[\alpha]_{\text{D}}^{22} -6.6$ (c 1.0, CHCl_3) for 82% ee, (*S*)]. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.87 (s, 3H), 2.46 (s, 1H), 7.30–7.50 (m, 8H), 7.73–7.75 (d, 2H, $J = 7.3$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.3, 70.4, 84.9, 92.4, 122.5, 125.0, 127.7, 128.29, 128.34, 128.5, 131.7, 145.6. HPLC: Daicel Chiralcel OD-H, hexane/isopropyl alcohol (IPA) = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 8.8$ min (*R*), $t_{\text{R}} = 10.9$ min (*S*).

(*S*)-(-)-1,3-Diphenylpent-1-yn-3-ol (**6bu**). The experimental data are in accordance with those reported in the previous literature.^{7c} 84.4 mg (95% yield). $[\alpha]_{\text{D}}^{30} -10.9$ (c 3.3, CHCl_3) for 89% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.03 (t, 3H, $J = 7.3$ Hz), 1.95–2.13 (m, 2H), 2.45 (s, 1H), 7.30–7.40 (m, 6H), 7.48–7.51 (m, 2H), 7.68–7.77 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 9.2, 38.4, 74.3, 86.1, 91.3, 122.6, 125.6, 127.7, 128.2, 128.3, 128.5, 131.7, 144.5. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 49:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 13.5$ min (*R*), $t_{\text{R}} = 17.0$ min (*S*).

(-)-4-Methyl-1,3-diphenylpent-1-yn-3-ol (**6cu**). The experimental data are in accordance with those reported in the previous literature.¹⁵ 79.0 mg (95% yield). $[\alpha]_{\text{D}}^{30} -1.8$ (c 0.90, CHCl_3) for 8% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 0.89 (d, 3H, $J = 7.2$ Hz), 1.14 (d, 3H, $J = 6.7$ Hz), 2.14–2.23 (qq, 1H, $J = 6.7, 7.2$ Hz), 2.41 (s, 1H), 7.28–7.39 (m, 6H), 7.47–7.53 (m, 2H), 7.66–7.71 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 17.5, 18.1, 40.5, 77.5, 86.9, 90.3, 122.7, 126.2, 127.6, 127.9, 128.3, 128.4, 131.7, 143.9. HPLC: Daicel Chiralpak AD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 9.9$ min (minor), $t_{\text{R}} = 14.6$ min (major).

(-)-2-(2-Methylphenyl)-4-phenylbut-3-yn-2-ol (**6du**). The experimental data are in accordance with those reported in the previous literature.^{7c} 59.6 mg (66% yield). $[\alpha]_{\text{D}}^{30} -9.4$ (c 1.4, CHCl_3) for 91% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.94 (s, 3H), 2.40 (s, 1H), 2.69 (s, 3H), 7.19–7.33 (m, 6H), 7.41–7.46 (m, 2H), 7.74–7.77 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 21.3, 31.0, 70.0, 84.6, 92.8, 122.7, 125.0, 125.8, 127.7, 128.3, 128.4, 131.6, 132.3, 135.7, 142.3. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 9.6$ min (minor), $t_{\text{R}} = 10.7$ min (major).

(-)-2-(3-Methylphenyl)-4-phenylbut-3-yn-2-ol (**6eu**). The experimental data are in accordance with those reported in the previous literature.^{7c} 78.2 mg (90% yield). $[\alpha]_{\text{D}}^{30} -5.6$ (c 0.86, CHCl_3) for 96% ee. [lit. $[\alpha]_{\text{D}}^{20} +5.8$ (c 1.21, CHCl_3) for 86% ee]. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.86 (s, 3H), 2.39 (s, 3H), 2.45 (s, 1H), 7.12 (d, 1H, $J = 7.3$ Hz), 7.25–7.35 (m, 4H), 7.47–7.54 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 21.6, 33.3, 70.3, 84.8, 92.6, 122.1, 122.6, 125.6, 128.2, 128.3, 128.4, 128.5, 131.7, 138.0, 145.6. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 8.2$ min (minor), $t_{\text{R}} = 9.9$ min (major).

(*S*)-(-)-2-(4-Methylphenyl)-4-phenylbut-3-yn-2-ol (**6fu**). The experimental data are in accordance with those reported in the previous literature.^{7c} 83.4 mg (94% yield). $[\alpha]_{\text{D}}^{28} -5.8$ (c 0.65, CHCl_3) for 96% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.86 (s, 3H), 2.36 (s, 3H), 2.41 (s, 1H), 7.19 (d, 2H, $J = 8.2$ Hz), 7.28–7.33 (m, 3H), 7.47–7.49 (m,

2H), 7.62 (d, 2H, $J = 8.2$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 21.0, 33.2, 70.2, 84.8, 92.6, 122.6, 124.9, 128.3, 128.4, 129.0, 131.7, 137.5, 142.8. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 8.1$ min (*R*), $t_{\text{R}} = 10.9$ min (*S*).

(-)-2-(4-Methoxyphenyl)-4-phenylbut-3-yn-2-ol (**6gu**). The experimental data are in accordance with those reported in the previous literature.^{4h} 104.5 mg (92% yield). $[\alpha]_{\text{D}}^{30} -6.9$ (c 1.3, CHCl_3) for 95% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.86 (s, 3H), 2.39 (s, 1H), 3.82 (s, 3H), 6.91 (m, 2H, $J = 9.2$ Hz), 7.32–7.35 (m, 3H), 7.47–7.49 (m, 2H), 7.64–7.67 (d, 2H, $J = 9.2$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.2, 55.3, 70.1, 84.8, 92.6, 113.6, 122.6, 126.3, 128.3, 128.5, 131.7, 137.9, 159.2. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 12.4$ min (minor), $t_{\text{R}} = 19.8$ min (major).

(*S*)-(-)-2-[(4-Trifluoromethyl)phenyl]-4-phenylbut-3-yn-2-ol (**6hu**). The experimental data are in accordance with those reported in the previous literature.^{7c} 114.2 mg (92% yield). $[\alpha]_{\text{D}}^{16} -12.1$ (c 0.65, CHCl_3) for 95% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.87 (s, 3H), 2.57 (s, 1H), 7.31–7.36 (m, 3H), 7.47–7.49 (m, 2H), 7.65 (d, 2H, $J = 8.3$ Hz), 7.85 (d, 2H, $J = 8.3$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.5, 70.1, 85.5, 91.6, 122.1, 124.1 (q, $J = 269$ Hz), 125.3 (q, $J = 39$ Hz), 128.3, 128.8, 130.4 (q, $J = 3$ Hz), 131.7, 149.5. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 7.6$ min (*R*), $t_{\text{R}} = 9.0$ min (*S*).

(-)-2-(4-Fluorophenyl)-4-phenylbut-3-yn-2-ol (**6iu**). The experimental data are in accordance with those reported in the previous literature.^{4m} 93.4 mg (93% yield). $[\alpha]_{\text{D}}^{30} -8.3$ (c 1.6, CHCl_3) for 95% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.85 (s, 3H), 2.48 (s, 1H), 7.04–7.08 (m, 2H), 7.31–7.35 (m, 3H), 7.47–7.49 (m, 2H), 7.68–7.71 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.5, 70.0, 85.1, 92.1, 115.1 (d, $J = 21$ Hz), 122.4, 126.8 (d, $J = 7$ Hz), 128.4, 128.6, 131.7, 141.5 (d, $J = 4$ Hz), 162.2 (d, $J = 244$ Hz). HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 8.3$ min (minor), $t_{\text{R}} = 10.4$ min (major).

(-)-2-(4-Bromophenyl)-4-phenylbut-3-yn-2-ol (**6ju**). The experimental data are in accordance with those reported in the previous literature.¹⁸ 128.5 mg (94% yield). $[\alpha]_{\text{D}}^{29} -5.9$ (c 0.88, CHCl_3) for 94% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.84 (s, 3H), 2.42 (s, 1H), 7.30–7.35 (m, 3H), 7.45–7.52 (m, 4H), 7.58–7.61 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.5, 70.0, 85.2, 91.8, 121.7, 122.2, 126.9, 128.3, 128.7, 131.4, 131.7, 144.8. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 9.3$ min (minor), $t_{\text{R}} = 11.4$ min (major).

(*S*)-(-)-2-(2-Naphthyl)-4-phenylbut-3-yn-2-ol (**6ku**). The experimental data are in accordance with those reported in the previous literature.^{4m} 109.1 mg (93% yield). $[\alpha]_{\text{D}}^{29} -16.5$ (c 1.4, CHCl_3) for 93% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.95 (s, 3H), 2.58 (s, 1H), 7.31–7.35 (m, 3H), 7.46–7.52 (m, 4H), 7.78–7.88 (m, 4H), 8.18 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.2, 70.5, 85.1, 92.4, 122.5, 123.4, 123.5, 126.1, 126.2, 127.6, 128.2, 128.3, 128.5, 131.8, 132.9, 133.0, 142.9. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 8.6$ min (*R*), $t_{\text{R}} = 11.1$ min (*S*).

(+)-2-(1-Naphthyl)-4-phenylbut-3-yn-2-ol (**6lu**). The experimental data are in accordance with those reported in the previous literature.^{4m} 27.0 mg (21% yield). $[\alpha]_{\text{D}}^{29} +17.8$ (c 0.73, CHCl_3) for 78% ee. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 2.15 (s, 3H), 2.67 (s, 1H), 7.24–7.29 (m, 3H), 7.42–7.55 (m, 5H), 7.83 (d, 1H, $J = 8.2$ Hz), 7.89 (d, 1H, $J = 8.0$ Hz), 7.98 (dd, 1H, $J = 1.2, 7.3$ Hz), 8.86 (d, 1H, $J = 8.9$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 31.8, 70.4, 85.5, 93.2, 122.6, 122.9, 124.9, 125.4, 125.5, 126.3, 128.3, 128.4, 129.0, 129.2, 130.1, 131.6, 134.7, 140.0. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_{\text{R}} = 12.5$ min (minor), $t_{\text{R}} = 15.8$ min (major).

(+)-4-Phenyl-2-(3,4,5-trimethoxyphenyl)but-3-yn-2-ol (**6mu**). 37.0 mg (26% yield). $[\alpha]_{\text{D}}^{30} +7.0$ (c 1.2, CHCl_3) for 98% ee. IR (neat): ν (cm^{-1}) 3431, 2935, 2835, 1593. $^1\text{H NMR}$ (CDCl_3 , 500 MHz): δ 1.87 (s, 3H), 2.50 (s, 1H), 3.86 (s, 3H), 3.90 (s, 6H), 6.98 (s, 2H), 7.31–7.35 (m, 3H), 7.46–7.48 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz): δ 33.3, 56.1, 60.8, 70.5, 84.9, 92.3, 102.3, 122.4, 128.4, 128.6, 131.6, 137.4, 141.4, 153.0. LRMS (FAB): m/z 335 ($\text{M} + \text{Na}^+$), 312, 129, 77. HRMS: calcd for $\text{C}_{19}\text{H}_{20}\text{O}_4\text{Na}$ 335.1259, found

335.1269. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, $t_R = 10.6$ min (minor), $t_R = 14.1$ min (major).

(*S*)-(+)-3-Methyl-1,5-diphenylpent-1-yn-3-ol (**6nu**). The experimental data are in accordance with those reported in the previous literature.^{4e} 80.3 mg (96% yield). $[\alpha]_D^{25} +7.4$ (c 1.9, CHCl₃) for 55% ee. ¹H NMR (CDCl₃, 500 MHz): δ 1.63 (s, 3H), 2.01–2.10 (m, 3H), 2.91–2.95 (m, 2H), 7.18–7.32 (m, 8H), 7.43–7.46 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 30.1, 31.3, 45.4, 68.5, 83.9, 92.4, 122.6, 125.9, 128.27, 128.33, 128.4, 131.7, 141.9. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 11.5$ min (R), $t_R = 15.6$ min (S).

(+)-3,4-Dimethyl-1-phenylpent-1-yn-3-ol (**6ou**). The experimental data are in accordance with those reported in the previous literature.^{4e} 78.6 mg (81% yield). $[\alpha]_D^{30} +5.9$ (c 0.98, CHCl₃) for 81% ee. ¹H NMR (CDCl₃, 500 MHz): δ 1.07 (d, 3H, $J = 6.7$ Hz), 1.11 (d, 3H, $J = 6.7$ Hz), 1.54 (s, 3H), 1.90 (qq, 1H, $J = 6.7, 6.7$ Hz), 2.02 (s, 1H), 7.28–7.31 (m, 3H), 7.40–7.44 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 17.5, 18.0, 27.2, 39.1, 72.1, 84.0, 92.0, 122.9, 128.17, 128.21, 131.6. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 6.0$ min (minor), $t_R = 8.2$ min (major).

(-)-2-(2-Thienyl)-3-phenylbut-3-yn-2-ol (**6pu**). The experimental data are in accordance with those reported in the previous literature.¹⁹ 98.3 mg (92% yield). $[\alpha]_D^{22} -7.7$ (c 0.65, CHCl₃) for 95% ee. ¹H NMR (CDCl₃, 500 MHz): δ 1.99 (s, 3H), 2.66 (s, 1H), 6.96–6.98 (m, 1H), 7.25–7.35 (m, 5H), 7.47–7.50 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 33.1, 67.7, 84.3, 91.7, 122.3, 124.0, 125.1, 126.7, 128.3, 128.7, 131.8, 150.6. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 10.6$ min (minor), $t_R = 13.4$ min (major).

(-)-4-Phenyl-2-(3-pyridinyl)but-3-yn-2-ol (**6qu**). The experimental data are in accordance with those reported in the previous literature.²⁰ 97.9 mg (96% yield). $[\alpha]_D^{33} -2.5$ (c 0.89, CHCl₃) for 94% ee [lit. $[\alpha]_D^{24} -0.9$ (c 1.0, CHCl₃) for 75% ee, (S)]. ¹H NMR (CDCl₃, 500 MHz): δ 1.88 (s, 3H), 3.51 (s, 1H), 7.27–7.35 (m, 4H), 7.46–7.51 (m, 2H), 8.01–8.03 (m, 1H), 8.54–8.56 (m, 1H), 8.97 (m, 1H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 33.4, 68.7, 85.6, 91.4, 122.1, 123.1, 128.4, 128.7, 131.7, 132.9, 141.3, 147.0, 148.8. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, $t_R = 9.9$ min (minor), $t_R = 12.3$ min (major).

(-)-4-Phenyl-2-(4-pyridinyl)but-3-yn-2-ol (**6ru**). The experimental data are in accordance with those reported in the previous literature.²¹ 85.7 mg (90% yield). $[\alpha]_D^{30} -4.3$ (c 0.52, CHCl₃) for 92% ee. ¹H NMR (CDCl₃, 500 MHz): δ 1.82 (s, 3H), 4.01–6.21 (brs, 1H), 7.27–7.35 (m, 3H), 7.41–7.44 (m, 2H), 7.62 (d, 2H, $J = 6.1$ Hz), 8.59 (d, 2H, $J = 6.1$ Hz). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 33.1, 68.9, 85.0, 91.6, 120.2, 122.1, 128.3, 128.6, 131.6, 149.2, 155.6. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 4:1, 1.0 mL/min, 254 nm, $t_R = 7.2$ min (minor), $t_R = 11.0$ min (major).

2-Phenyl-3-yn-2-ol (**6av**). The experimental data are in accordance with those reported in the previous literature.²² 82.3 mg (95% yield). $[\alpha]_D^{30} -0.3$ (c 1.2, CHCl₃) for 90% ee. ¹H NMR (CDCl₃, 500 MHz): δ 0.93 (t, 3H, $J = 7.3$ Hz), 1.39–1.58 (m, 4H), 1.74 (s, 3H), 2.25–2.34 (m, 3H), 7.26–7.37 (m, 3H), 7.65–7.67 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 13.6, 18.4, 22.0, 30.7, 33.6, 70.1, 83.7, 85.7, 125.0, 127.5, 128.2, 146.2. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 200:1, 1.0 mL/min, 254 nm: $t_R = 20.7$ min (minor), $t_R = 22.5$ min (major).

(-)-2-Phenyl-3-yn-2-ol (**6aw**). The experimental data are in accordance with those reported in the previous literature.²³ 110.1 mg (99% yield). $[\alpha]_D^{32} -2.3$ (c 0.95, CHCl₃) for 92% ee. ¹H NMR (CDCl₃, 500 MHz): δ 0.88 (t, 3H, $J = 6.7$ Hz), 1.28–1.42 (m, 10H), 1.51–1.58 (m, 2H), 1.74 (s, 3H), 2.25–2.29 (m, 3H), 7.25–7.39 (m, 3H), 7.64–7.67 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 14.1, 18.7, 22.7, 28.6, 28.9, 29.1, 29.2, 31.8, 33.5, 70.1, 83.7, 85.8, 125.0, 127.5, 128.2, 146.2. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 99:1, 1.0 mL/min, 254 nm, $t_R = 12.3$ min (minor), $t_R = 13.3$ min (major).

(-)-4-(1-Cyclohexenyl)-2-phenylbut-3-yn-2-ol (**6ax**). The experimental data are in accordance with those reported in the previous literature.¹⁹ 101.2 mg (99% yield). $[\alpha]_D^{25} -2.0$ (c 1.3, CHCl₃) for 95%

ee. ¹H NMR (CDCl₃, 500 MHz): δ 1.56–1.68 (m, 4H), 1.77 (s, 3H), 2.07–2.17 (m, 4H), 2.34 (s, 1H), 6.16 (t, 1H, $J = 1.9$ Hz), 7.25–7.39 (m, 3H), 7.65–7.67 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 21.4, 22.2, 25.6, 29.2, 33.4, 70.3, 86.7, 89.8, 120.1, 125.0, 127.5, 128.2, 135.4, 146.0. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 99:1, 1.0 mL/min, 254 nm, $t_R = 16.1$ min (minor), $t_R = 17.5$ min (major).

(-)-1-(Benzyloxy)-4-phenylpent-2-yn-4-ol (**6ay**). The experimental data are in accordance with those reported in the previous literature.²⁴ 115.0 mg (99% yield). $[\alpha]_D^{31} -4.5$ (c 2.0, CHCl₃) for 87% ee. ¹H NMR (CDCl₃, 500 MHz): δ 1.76 (s, 3H), 2.51 (s, 1H), 4.23 (s, 2H), 4.61 (s, 2H), 7.24–7.36 (m, 8H), 7.63–7.65 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 33.1, 57.4, 69.9, 71.7, 80.8, 90.0, 124.8, 127.7, 127.9, 128.1, 128.3, 128.4, 137.3, 145.3. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 14.2$ min (minor), $t_R = 16.0$ min (major).

(+)-2-Phenyl-4-(trimethylsilyl)but-3-yn-2-ol (**6az**). The experimental data are in accordance with those reported in the previous literature.²⁵ 88.7 mg (91% yield). $[\alpha]_D^{28} +6.1$ (c 1.5, CHCl₃) for 91% ee. ¹H NMR (CDCl₃, 500 MHz): δ 0.21 (s, 9H), 1.76 (s, 3H), 2.33 (s, 1H), 7.27–7.31 (m, 1H), 7.34–7.38 (m, 2H), 7.64–7.66 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ -0.1, 33.3, 70.2, 89.3, 108.7, 124.9, 127.7, 128.3, 145.4. HPLC: Daicel Chiralpak AS-H, hexane/IPA = 99:1, 0.5 mL/min, 254 nm, $t_R = 24.0$ min (minor), $t_R = 26.2$ min (major).

Representative Procedure for Preparation of Esters 7a.

Reduction of alkynes to alkenes: A solution of Red-Al in toluene (65%, 4.0 equiv) was added to a solution of propargyl alcohol **6bu** in anhydrous Et₂O at 0 °C via a syringe. The reaction mixture was allowed to warm slowly to room temperature and stirred for 4 h. Then, the mixture was cooled to 0 °C and quenched by dropwise addition of MeOH. The resulting solution was allowed to warm to rt and diluted with EtOAc. The solution was washed with saturated aq Rochelle's salt (sodium potassium tartrate), and the organic layer was dried over MgSO₄. After filtration and concentration, the resulting yellowish oil was purified by column chromatography (eluent: hexane/EtOAc = 8:1) to afford the corresponding alkene.

Ozonolysis of alkenes to aldehydes: Ozone was bubbled into a solution of the alkene in CH₂Cl₂ at -78 °C until a blue color persisted. Oxygen was then passed through the solution to remove the ozone, and then triphenylphosphine (1 equiv) was added at -78 °C. The resulting mixture was stirred for 1 h at rt. The mixture was concentrated under reduced pressure to afford an oil, which was purified by column chromatography (eluent: hexane/EtOAc = 6:1) to afford the corresponding aldehyde as an oil.

Oxidation of aldehyde to ester: NaHCO₃ (33 equiv) was added to a solution of the aldehyde in MeOH/water (9:1 v/v), followed by the addition of bromine (7.5 equiv) over 30 min under vigorous stirring at rt. After the solution was stirred for 2 h, the excess bromine was decomposed with Na₂S₂O₃. The resulting solution was filtered, and the filtrate was extracted with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄. After concentration in vacuo, the crude product obtained was purified by column chromatography (eluent: hexane/CH₂Cl₂ = 3:2 to 1:3) to afford **7b** (38 yield from **6bu**) as a colorless oil.

(*S*)-(+)-Methyl 2-hydroxy-2-phenylbutanoate (**7b**). The experimental data are in accordance with those reported in the previous literature.¹⁶ 38% yield from **6bu**. $[\alpha]_D^{24} +21.5$ (c 0.50, CHCl₃) for 71% ee [lit. $[\alpha]_D^{25} +34.1$ (c 0.49, CHCl₃) for 83% ee, (S)]. ¹H NMR (CDCl₃, 400 MHz): δ 0.92 (t, 3H, $J = 7.2$ Hz), 1.99–2.12 (m, 1H), 2.19–2.28 (m, 2H), 3.72 (s, 1H), 3.78 (s, 3H), 7.26–7.37 (m, 3H), 7.59 (d, 2H, $J = 8.2$ Hz). HPLC: Daicel Chiralpak AD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm: $t_R = 7.8$ min (S), $t_R = 8.5$ min (R).

(*S*)-(+)-Methyl 2-hydroxy-2-(4-methylphenyl)propanoate (**7f**). The experimental data are in accordance with those reported in the previous literature.¹⁷ 11% yield from **6fu**. $[\alpha]_D^{24} +25.3$ (c 0.16, CHCl₃) for 81% ee [lit. $[\alpha]_D^{25} +54$ (c 1.6, CHCl₃) for 85% ee, (S)]. ¹H NMR (CDCl₃, 400 MHz): δ 1.77 (s, 3H), 2.34 (s, 3H), 3.68 (s, 1H), 3.77 (s, 3H), 7.16 (d, 2H, $J = 8.2$ Hz), 7.42 (d, 2H, $J = 8.2$ Hz). HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 0.5 mL/min, 254 nm, $t_R = 15.0$ min (S), $t_R = 18.3$ min (R).

(*S*)-(+)-Methyl 2-Hydroxy-2-[4-(trifluoromethyl)phenyl]propanoate (**7h**). The experimental data are in accordance with those reported in the previous literature.¹⁷ 21% yield from **6hu**. $[\alpha]_D^{24} +28.9$ (c 0.36, CHCl₃) for 71% ee [lit. $[\alpha]_D^{24} +6.1$ (c 1.8, CHCl₃) for 16% ee, (S)]. ¹H NMR (CDCl₃, 400 MHz): δ 1.80 (s, 3H), 3.80 (s, 3H), 3.82 (s, 1H), 7.60–7.62 (m, 2H), 7.69–7.71 (m, 2H). HPLC: Daicel Chiralcel OD-H, hexane/IPA = 49:1, 0.5 mL/min, 254 nm, $t_R = 16.5$ min (R), $t_R = 17.8$ min (S).

(*S*)-(+)-Methyl 2-Hydroxy-2-(2-naphthyl)propanoate (**7k**). The experimental data are in accordance with those reported in the previous literature.¹⁷ 31% yield from **6ku**. $[\alpha]_D^{18} +43.4$ (c 0.90, CHCl₃) for 88% ee [lit. $[\alpha]_D^{26} +45$ (c 1.7, CHCl₃) for 82% ee, (S)]. ¹H NMR (CDCl₃, 400 MHz): δ 1.89 (s, 3H), 3.79 (s, 3H), 3.86 (s, 1H), 7.46–7.51 (m, 2H), 7.64 (dd, 1H, $J = 1.8, 8.7$ Hz), 7.81–7.87 (m, 3H), 8.01–8.07 (m, 1H). HPLC: Daicel Chiralcel OJ-H, hexane/IPA = 9:1, 0.5 mL/min, 254 nm, $t_R = 52.2$ min (S), $t_R = 67.3$ min (R).

(*S*)-(+)-Methyl 2-Hydroxy-2-methyl-4-phenylbutanoate (**7n**). The experimental data are in accordance with those reported in the previous literature.¹⁷ 59% yield from **6nu**. $[\alpha]_D^{25} +17.7$ (c 1.5, CHCl₃) for 39% ee [lit. $[\alpha]_D^{25} +7.2$ (c 1.5, CHCl₃) for 19% ee, (S)]. ¹H NMR (CDCl₃, 400 MHz): δ 1.45 (s, 3H), 1.94–2.10 (m, 2H), 2.42–2.50 (m, 1H), 2.75–2.83 (m, 1H), 3.25 (s, 1H), 3.73 (s, 3H), 7.15–7.19 (m, 3H), 7.25–7.30 (m, 2H). HPLC: Daicel Chiralcel OJ-H, hexane/IPA = 49:1, 0.5 mL/min, 254 nm, $t_R = 25.8$ min (R), $t_R = 27.1$ min (S).

Representative Procedure for Asymmetric Alkylations of Aldehydes. Lithium acetylide **4u** and lithium binaphtholate **1b** were prepared by the addition of *n*-BuLi (1.65 M in hexane, 0.59 mL, 0.98 mmol) to the solution of (R)-3,3'-diphenyl-1,1'-binaphthalene-2,2'-diol (22 mg, 0.049 mmol) and phenylacetylene (0.11 mL, 0.98 mmol) in THF (1.0 mL) at –78 °C. A solution of benzaldehyde **2a** (0.050 mL, 0.49 mmol) in THF (1.0 mL) was added to the reaction mixture over 10 min at the same temperature and stirred for an additional 1 h. After quenching with saturated aq NH₄Cl, the resulting solution was extracted with EtOAc. The organic layer was washed with saturated aq NaHCO₃ and brine. After drying over Na₂SO₄, the solvent was removed under vacuum, and the residue was purified by silica gel column chromatography (hexane/CH₂Cl₂ = 1:1 v/v), affording **5au** (99.2 mg, 97%) as an oil. The ee was determined to be 75% by chiral HPLC with Daicel Chiralcel OD-H column.

(*S*)-1,3-Diphenylprop-2-yn-1-ol (**5au**). The experimental data are in accordance with those reported in the previous literature.²⁶ 99.2 mg (97% yield). $[\alpha]_D^{19} -1.8$ (c 2.0, CHCl₃) for 75% ee [lit. $[\alpha]_D^{27} -2.4$ (c 1.2, CHCl₃) for 86% ee, (S)]. ¹H NMR (CDCl₃, 500 MHz): δ 2.29 (d, 1H, $J = 6.1$ Hz), 5.69 (d, 1H, $J = 6.1$ Hz), 7.28–7.48 (m, 8H), 7.61 (d, 2H, $J = 7.3$ Hz). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 65.1, 86.7, 88.7, 122.4, 126.7, 128.3, 128.4, 128.6, 128.7, 131.7, 140.6. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, $t_R = 14.5$ min (R), $t_R = 23.6$ min (S).

(*S*)-(-)-1-Phenylhept-2-yn-1-ol (**5av**). The experimental data are in accordance with those reported in the previous literature.²⁶ 91.3 mg (99% yield). $[\alpha]_D^{24} -2.5$ (c 1.0, CHCl₃) for 15% ee [lit. $[\alpha]_D^{25} -18.1$ (c 1.3, CHCl₃) for 75% ee, (S)]. ¹H NMR (CDCl₃, 500 MHz): δ 0.92 (t, 3H, $J = 7.3$ Hz), 1.40–1.57 (m, 4H), 2.06 (d, 1H, $J = 6.1$ Hz), 2.26–2.31 (m, 2H), 5.45 (d, 1H, $J = 6.1$ Hz), 7.30–7.40 (m, 3H), 7.55 (d, 2H, $J = 7.0$ Hz). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 13.7, 18.5, 22.0, 30.6, 64.9, 79.9, 87.7, 126.6, 128.2, 128.5, 141.3. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 8.9$ min (S), $t_R = 14.1$ min (R).

(*-*)-1-Phenylundec-2-yn-1-ol (**5aw**). The experimental data are in accordance with those reported in the previous literature.²⁷ 112.2 mg (94% yield). $[\alpha]_D^{33} -2.5$ (c 0.81, CHCl₃) for 21% ee. ¹H NMR (CDCl₃, 500 MHz): δ 0.88 (t, 3H, $J = 6.7$ Hz), 1.23–1.58 (m, 12H), 2.07 (d, 1H, $J = 6.1$ Hz), 2.24–2.29 (m, 2H), 5.44 (d, 1H, $J = 6.1$ Hz), 7.30–7.39 (m, 3H), 7.54 (d, 2H, $J = 7.0$ Hz). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 14.1, 18.8, 22.7, 28.6, 28.9, 29.1, 29.2, 31.8, 64.9, 79.9, 87.8, 126.6, 128.1, 128.5, 141.3. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 7.2$ min (major), $t_R = 11.3$ min (minor).

(*S*)-(-)-3-(1-Cyclohexenyl)-1-phenylprop-2-yn-1-ol (**5ax**). The experimental data are in accordance with those reported in the

previous literature.^{8b} 96.0 mg (61% yield). $[\alpha]_D^{24} -2.8$ (c 1.1, CHCl₃) for 61% ee [lit. $[\alpha]_D^{15} +6.7$ (c 1.31, CHCl₃) for 95% ee, (R)]. ¹H NMR (CDCl₃, 500 MHz): δ 1.55–1.67 (m, 4H), 2.09–2.15 (m, 5H), 5.57 (d, 1H, $J = 6.4$ Hz), 6.15–6.17 (m, 1H), 7.30–7.40 (m, 3H), 7.55–7.57 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 21.4, 22.2, 25.6, 29.0, 65.0, 86.0, 88.6, 120.0, 126.7, 128.2, 128.5, 135.7, 141.0. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 11.9$ min (major), $t_R = 16.9$ min (minor).

(*-*)-4-(Benzyloxy)-1-phenylbut-2-yn-1-ol (**5ay**). The experimental data are in accordance with those reported in the previous literature.²⁸ 121.9 mg (98% yield). $[\alpha]_D^{25} -4.8$ (c 0.15, CHCl₃) for 42% ee. ¹H NMR (CDCl₃, 500 MHz): δ 2.23 (d, 1H, $J = 5.8$ Hz), 4.26 (s, 2H), 4.60 (s, 2H), 5.53 (d, 1H, $J = 5.8$ Hz), 7.28–7.41 (m, 8H), 7.54 (d, 2H, $J = 7.3$ Hz). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 57.4, 64.6, 71.8, 82.7, 86.3, 126.6, 127.9, 128.1, 128.2, 128.4, 128.6, 137.3, 140.4. HPLC: Daicel Chiralpak AD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, $t_R = 14.2$ min (major), $t_R = 16.3$ min (minor).

(*S*)-(-)-1-Phenyl-3-(trimethylsilyl)but-2-yn-1-ol (**5az**). The experimental data are in accordance with those reported in the previous literature.²⁹ 91.3 mg (91% yield). $[\alpha]_D^{25} -11.6$ (c 0.13, CHCl₃) for 44% ee [lit. $[\alpha]_D^{25} +11.2$ (c 0.58, CHCl₃) for 52% ee, (R)]. ¹H NMR (CDCl₃, 500 MHz): δ 0.21 (s, 9H), 2.18 (d, 1H, $J = 6.4$ Hz), 5.46 (d, 1H, $J = 6.4$ Hz), 7.31–7.41 (m, 3H), 7.53–7.56 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ -0.2, 65.0, 91.6, 104.9, 126.7, 128.3, 128.6, 140.3. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 19:1, 1.0 mL/min, 254 nm, $t_R = 4.6$ min (S), $t_R = 6.3$ min (R).

(*S*)-(-)-1-(4-Methoxyphenyl)-3-phenylprop-2-yn-1-ol (**5bu**). The experimental data are in accordance with those reported in the previous literature.²⁶ 97.7 mg (99% yield). $[\alpha]_D^{24} -8.8$ (c 1.2, CHCl₃) for 75% ee [lit. $[\alpha]_D^{27} -4.2$ (c 1.7, CHCl₃) for 80% ee, (S)]. ¹H NMR (CDCl₃, 500 MHz): δ 2.21 (d, 1H, $J = 6.1$ Hz), 3.83 (s, 3H), 5.64 (d, 1H, $J = 6.1$ Hz), 6.91–6.94 (m, 2H), 7.28–7.32 (m, 3H), 7.45–7.48 (m, 2H), 7.52–7.56 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 55.3, 64.8, 86.5, 88.9, 114.0, 122.5, 128.2, 128.3, 128.6, 131.7, 133.0, 159.8. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 4:1, 1.0 mL/min, 254 nm, $t_R = 8.6$ min (R), $t_R = 13.6$ min (S).

(*S*)-(-)-1-(4-Chlorophenyl)-3-phenylprop-2-yn-1-ol (**5cu**). The experimental data are in accordance with those reported in the previous literature.²⁶ 116.4 mg (98% yield). $[\alpha]_D^{22} -5.9$ (c 0.98, CHCl₃) for 71% ee [lit. $[\alpha]_D^{27} -7.9$ (c 1.4, CHCl₃) for 84% ee, (S)]. ¹H NMR (CDCl₃, 500 MHz): δ 2.33 (d, 1H, $J = 6.1$ Hz), 5.66 (d, 1H, $J = 6.1$ Hz), 7.29–7.58 (m, 9H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 64.4, 87.0, 88.2, 122.1, 128.1, 128.3, 128.8, 131.7, 134.2, 139.1. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, $t_R = 9.5$ min (R), $t_R = 28.3$ min (S).

(*S*)-(+)-1-(2-Naphthyl)-3-phenylprop-2-yn-1-ol (**5du**). The experimental data are in accordance with those reported in the previous literature.³⁰ 124.3 mg (98% yield). $[\alpha]_D^{18} +7.0$ (c 1.6, CHCl₃), 65% ee [lit. $[\alpha]_D^{27} -7.8$ (c 0.5, CHCl₃) for 87% ee, (R)]. ¹H NMR (CDCl₃, 500 MHz): 2.35 (d, 1H, $J = 6.1$ Hz), 5.86 (d, 1H, $J = 6.1$ Hz), 7.32–7.33 (m, 3H), 7.48–7.51 (m, 4H), 7.71–7.73 (m, 1H), 7.84–7.89 (m, 3H), 8.04 (s, 1H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 65.3, 87.0, 88.6, 122.4, 124.6, 125.5, 126.3, 127.7, 128.2, 128.3, 128.61, 128.64, 131.8, 133.2, 133.3, 138.0. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 4:1, 1.0 mL/min, 254 nm, $t_R = 9.6$ min (R), $t_R = 23.5$ min (S).

(*-*)-3-Phenyl-1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-ol (**5eu**). The experimental data are in accordance with those reported in the previous literature.³¹ 139.4 mg (95% yield). $[\alpha]_D^{19} -6.1$ (c 1.3, CHCl₃) for 82% ee. ¹H NMR (CDCl₃, 500 MHz): δ 2.26 (d, 1H, $J = 6.1$ Hz), 3.86 (s, 3H), 3.91 (s, 6H), 5.64 (d, 1H, $J = 6.1$ Hz), 6.87 (s, 2H), 7.33–7.36 (m, 3H), 7.47–7.49 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ 56.2, 60.9, 65.3, 86.7, 88.5, 103.8, 128.4, 128.7, 131.7, 136.2, 153.4. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 2:1, 1.0 mL/min, 254 nm, $t_R = 7.0$ min (minor), $t_R = 15.9$ min (major).

(*S*)-(+)-1-Cyclohexyl-3-phenylprop-2-yn-1-ol (**5fu**). The experimental data are in accordance with those reported in the previous literature.^{8b} 79.6 mg (90% yield). $[\alpha]_D^{19} +6.9$ (c 1.2, CHCl₃) for 58% ee [lit. $[\alpha]_D^{25} -11.4$ (c 3.17, CHCl₃) for 97% ee, (R)]. ¹H NMR (CDCl₃, 500 MHz): δ 1.08–1.32 (m, 5H), 1.60–1.99 (m, 7H), 4.38 (t, 1H, $J = 5.8$ Hz), 7.28–7.32 (m, 3H), 7.41–7.47 (m, 2H). ¹³C{¹H}

NMR (CDCl₃, 125 MHz): δ 25.9, 26.4, 28.2, 28.7, 44.3, 67.7, 85.7, 89.2, 122.8, 128.27, 128.32, 131.7. HPLC: Daicel Chiralcel OD-H, hexane/IPA = 9:1, 1.0 mL/min, 254 nm, t_R = 5.9 min (R), t_R = 10.8 min (S).

■ ASSOCIATED CONTENT

📄 Supporting Information

Copies of ¹H and ¹³C NMR spectra and HPLC profiles. This material is available free of charge via the Internet at <http://pubs.acs.org/>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: nakajima@gpo.kumamoto-u.ac.jp.

Present Address

[§]5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Young Scientists (B) from The Ministry of Education, Culture, Sports, Science and Technology, Japan.

■ REFERENCES

- Wu, G.; Huang, M. *Chem. Rev.* **2006**, *106*, 2596–2616.
- For reviews on asymmetric alkynylations, see: (a) Frantz, D. E.; Fässler, R.; Tomooka, C. S.; Carreira, E. M. *Acc. Chem. Res.* **2000**, *33*, 373–381. (b) Pu, L. *Tetrahedron* **2003**, *59*, 9873–9886. (c) Cozzi, P. G.; Hilgraf, R.; Zimmermann, N. *Eur. J. Org. Chem.* **2004**, 4095–4105. (d) Trost, B. M.; Weiss, A. H. *Adv. Synth. Catal.* **2009**, *351*, 963–983. (e) Tyrrell, E. *Curr. Org. Chem.* **2009**, *13*, 1540–1552. (f) Mao, J.; Xie, G. *Curr. Org. Chem.* **2009**, *13*, 1553–1564. (g) Lin, L.; Wang, R. *Curr. Org. Chem.* **2009**, *13*, 1565–1576. (h) Ohshima, T. In *Comprehensive Chirality*; Carreira, E. M., Yamamoto, H., Eds.; Elsevier: New York, 2012; Vol. 4, pp 355–377.
- For enantioselective alkynylations with alkynylmetal reagents, see: (a) Niwa, S.; Soai, K. *J. Chem. Soc., Perkin Trans. 1* **1990**, 937–943. (b) Ishizaki, M.; Hoshino, O. *Tetrahedron: Asymmetry* **1994**, *5*, 1901–1904. (c) Corey, E. J.; Cimprich, K. A. *J. Am. Chem. Soc.* **1994**, *116*, 3151–3152. (d) Tan, L.; Chen, C.-Y.; Tillyer, R. D.; Grabowski, E. J. J.; Reider, P. J. *Angew. Chem., Int. Ed.* **1999**, *38*, 711–713.
- For alkylzinc-mediated alkynylations, see: (a) Li, Z.; Upadhyay, V.; DeCamp, A. E.; DiMichele, L.; Reider, P. J. *Synthesis* **1999**, 1453–1458. (b) Lu, G.; Li, X.; Zhou, Z.; Chan, W. L.; Chan, A. S. C. *Tetrahedron: Asymmetry* **2001**, *12*, 2147–2152. (c) Xu, H.-M.; Pu, L. *Org. Lett.* **2002**, *4*, 4555–4558. (d) Braga, A. L.; Appelt, H. R.; Silveira, C. C.; Wessjohann, L. A.; Schneider, P. H. *Tetrahedron* **2002**, *58*, 10413–10416. (e) Cozzi, P. G. *Angew. Chem., Int. Ed.* **2003**, *42*, 2895–2898. (f) Li, M.; Zhu, X.-Z.; Yuan, K.; Cao, B.-X.; Hou, X.-L. *Tetrahedron: Asymmetry* **2004**, *15*, 219–222. (g) Kang, Y.-F.; Liu, L.; Wang, R.; Yan, W.-J.; Zhou, Y.-F. *Tetrahedron: Asymmetry* **2004**, *15*, 3155–3159. (h) Liu, L.; Kang, Y.-F.; Wang, R.; Zhou, Y.-F.; Chen, C.; Ni, M.; Gong, M.-Z. *Tetrahedron: Asymmetry* **2004**, *15*, 3757–3761. (i) Dahmen, S. *Org. Lett.* **2004**, *6*, 2113–2116. (j) Saito, B.; Katsuki, T. *Synlett* **2004**, 1557–1560. (k) Kang, Y.-F.; Liu, L.; Wang, R.; Zhou, Y.-F.; Yan, W.-J. *Adv. Synth. Catal.* **2005**, *347*, 243–247. (l) Mao, J.; Wan, B.; Wu, F.; Lu, S. *J. Mol. Catal. A: Chem.* **2005**, *237*, 126–131. (m) Wolf, C.; Liu, S. *J. Am. Chem. Soc.* **2006**, *128*, 10996–10997. (n) Chen, C.; Hong, L.; Xu, Z.-Q.; Liu, L.; Wang, R. *Org. Lett.* **2006**, *8*, 2277–2280. (o) Li, Z.-B.; Liu, T.-D.; Pu, L. *J. Org. Chem.* **2007**, *72*, 4340–4343. (p) Yang, X.-F.; Hirose, T.; Zhang, G.-Y. *Tetrahedron: Asymmetry* **2007**, *18*, 2668–2673. (q) Wang, M.-C.; Zhang, Q.-J.; Zhao, W.-X.; Wang, X.-D.; Ding, X.; Jing, T.-T.; Song, M.-P. *J. Org. Chem.* **2008**, *73*, 168–176. (r) Li, H.; Huang, Y.; Jin, W.; Xue, F.; Wan, B. *Tetrahedron Lett.* **2008**, *49*, 1686–1689.

(5) For zinc triflate-catalyzed alkynylations, see: (a) Anand, N. K.; Carreira, E. M. *J. Am. Chem. Soc.* **2001**, *123*, 9687–9688. (b) Jiang, B.; Chen, Z.; Tang, X. *Org. Lett.* **2002**, *4*, 3451–3453. (c) Fässler, R.; Tomooka, C. S.; Frantz, D. E.; Carreira, E. M. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 5843–5845.

(6) For titanium catalysis, see: (a) Lu, G.; Li, X.; Chan, W. L.; Chan, A. S. C. *Chem. Commun.* **2002**, 172–173. (b) Li, X.; Lu, G.; Kwok, W. H.; Chan, A. S. C. *J. Am. Chem. Soc.* **2002**, *124*, 12636–12637. (c) Moore, D.; Pu, L. *Org. Lett.* **2002**, *4*, 1855–1857. (d) Gao, G.; Moore, D.; Xie, R.-G.; Pu, L. *Org. Lett.* **2002**, *4*, 4143–4146. (e) Wu, K.-H.; Gau, H.-M. *Organometallics* **2004**, *23*, 580–588. (f) Liu, Q.-Z.; Xie, N.-S.; Luo, Z.-B.; Cui, X.; Cun, L.-F.; Gong, L.-Z.; Mi, A.-Q.; Jiang, Y.-Z. *J. Org. Chem.* **2003**, *68*, 7921–7924. (g) Zhou, Y.; Wang, R.; Xu, Z.; Yan, W.; Liu, L.; Kang, Y.; Han, Z. *Org. Lett.* **2004**, *6*, 4147–4149. (h) Ni, M.; Wang, R.; Han, Z.-J.; Mao, B.; Da, C.-S.; Liu, L.; Chen, C. *Adv. Synth. Catal.* **2005**, *347*, 1659–1665. (i) Xu, Z.; Mao, J.; Zhang, Y. *Org. Biomol. Chem.* **2008**, *6*, 1288–1292. (j) Yue, Y.; Turlington, M.; Yu, X.-Q.; Pu, L. *J. Org. Chem.* **2009**, *74*, 8681–8689.

(7) For copper catalysis, see: (a) Lu, G.; Li, X.; Jia, X.; Chan, W. L.; Chan, A. S. C. *Angew. Chem., Int. Ed.* **2003**, *42*, 5057–5058. (b) Liu, L.; Wang, R.; Kang, Y.-F.; Cai, H.-Q.; Chen, C. *Synlett* **2006**, 1245–1249. (c) Lu, G.; Li, X.; Li, Y.-M.; Kwong, F. Y.; Chan, A. S. C. *Adv. Synth. Catal.* **2006**, *348*, 1926–1933. (d) Motoki, R.; Kanai, M.; Shibasaki, M. *Org. Lett.* **2007**, *9*, 2997–3000. (e) Asano, Y.; Hara, K.; Ito, H.; Sawamura, M. *Org. Lett.* **2007**, *9*, 3901–3904.

(8) For other metal catalysis, see: (a) Takita, R.; Fukuta, Y.; Tsuji, R.; Ohshima, T.; Shibasaki, M. *Org. Lett.* **2005**, *7*, 1363–1366. (b) Takita, R.; Yakura, K.; Ohshima, T.; Shibasaki, M. *J. Am. Chem. Soc.* **2005**, *127*, 13760–13761. (c) Dhondi, P. K.; Carberry, P.; Choi, L. B.; Chisholm, J. D. *J. Org. Chem.* **2007**, *72*, 9590–9596. (d) Ito, J.-I.; Asai, R.; Nishiyama, H. *Org. Lett.* **2010**, *12*, 3860–3862. (e) Ohshima, T.; Kawabata, T.; Takeuchi, Y.; Kakinuma, T.; Iwasaki, T.; Yonezawa, T.; Murakami, H.; Nishiyama, H.; Mashima, K. *Angew. Chem., Int. Ed.* **2011**, *50*, 6296–6300.

(9) (a) Mukaiyama, T.; Suzuki, K.; Soai, K.; Sato, T. *Chem. Lett.* **1979**, 447–448. (b) Mukaiyama, T.; Suzuki, K. *Chem. Lett.* **1980**, 255–256.

(10) (a) Thompson, A. S.; Corley, E. G.; Huntington, M. F.; Grabowski, E. J. *J. Tetrahedron Lett.* **1995**, *36*, 8937–8940. (b) Thompson, A.; Corley, E. G.; Huntington, M. F.; Grabowski, E. J. J.; Remenar, J. F.; Collum, D. B. *J. Am. Chem. Soc.* **1998**, *120*, 2028–2038. (c) Xu, F.; Reamer, R. A.; Tillyer, R.; Cummins, J. M.; Grabowski, E. J. J.; Reider, P. J.; Collum, D. B.; Hoffman, J. C. *J. Am. Chem. Soc.* **2000**, *122*, 11212–11218.

(11) For enantioselective alkynylation of lithium acetylide using titanium catalyst, see: Cozzi, P. G.; Alesi, S. *Chem. Commun.* **2004**, 2448–2449.

(12) Tanaka, K.; Kukita, K.; Ichibakase, T.; Kotani, S.; Nakajima, M. *Chem. Commun.* **2011**, 47, 5614–5616.

(13) The enolization of ketone **3d** also decreased the product yield.

(14) Arnoldi, A.; Betto, E.; Farina, G.; Formigoni, A.; Galli, R.; Griffini, A. *Pestic. Sci.* **1982**, *13*, 670–678.

(15) Ueda, T.; Tanaka, K.; Ichibakase, T.; Orito, Y.; Nakajima, M. *Tetrahedron* **2010**, *66*, 7726–7731.

(16) Wieland, L. C.; Deng, H.; Snapper, M. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2005**, *127*, 15453–15456.

(17) We, H.-L.; Wu, P.-Y.; Shen, Y.-Y.; Uang, B.-J. *J. Org. Chem.* **2008**, *73*, 6445–6447.

(18) Cozzi, P. G.; Rudolph, J.; Bolm, C.; Norrby, P.-O.; Tomasini, C. *J. Org. Chem.* **2005**, *14*, 5733–5736.

(19) Wang, Q.; Zhang, B.; Hu, G.; Chen, C.; Zhao, Q.; Wang, R. *Org. Biomol. Chem.* **2007**, *5*, 1161–1163.

(20) Liu, J.; Lin, J.; Song, L. *Tetrahedron Lett.* **2012**, *53*, 2160–2163.

(21) Cussac, M.; Boucherie, A.; Pierre, J.-L.; Hche, J. *Eur. J. Med. Chem.* **1974**, *9*, 651–657.

(22) Lettan, R. B., II; Scheidt, K. A. *Org. Lett.* **2005**, *7*, 3227–3230.

(23) An, S. E.; Jeong, J.; Baskar, B.; Lee, J.; Seo, J.; Rhee, Y. H. *Chem.—Eur. J.* **2009**, *15*, 11837–11841.

- (24) Ishikawa, T.; Mizuta, T.; Hagiwara, K.; Aikawa, T.; Kudo, T.; Saito, S. *J. Org. Chem.* **2003**, *68*, 3702–3705.
- (25) Kunishima, M.; Nakata, D.; Tanaka, S.; Hioki, K.; Tani, S. *Tetrahedron* **2000**, *56*, 9927–9935.
- (26) Wu, P.-Y.; Wu, H.-L.; Shen, Y.-Y.; Uang, B.-J. *Tetrahedron: Asymmetry* **2009**, *20*, 1837–1841.
- (27) Chen, D.-W.; Ochiai, M. *J. Org. Chem.* **1999**, *64*, 6804–6814.
- (28) Nakano, T.; Soeta, T.; Endo, K.; Inomata, K.; Ukaji, Y. *J. Org. Chem.* **2013**, *78*, 12654–12661.
- (29) Blay, G.; Cardona, L.; Fernández, I.; Marco-Alexandre, A.; Muñoz, M. C.; Pedro, J. R. *Org. Biomol. Chem.* **2009**, *7*, 4301–4308.
- (30) Usanov, D. L.; Yamamoto, H. *J. Am. Chem. Soc.* **2011**, *133*, 1286–1289.
- (31) Reddy, C. R.; Vijaykumar, J.; Grée, R. *Synthesis* **2013**, *45*, 830–836.